Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Fbn2em1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Fbn2em1flox/Cya

Common Name
Fbn2-flox
Product ID
S-CKO-02370
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-14119-Fbn2-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Fbn2-flox Mouse (Catalog S-CKO-02370) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Fbn2-flox
Strain ID
CKOCMP-14119-Fbn2-B6J-VA
Gene Name
Fbn2
Product ID
S-CKO-02370
Gene Alias
sy, sne, Fib-2, mKIAA4226
Background
C57BL/6JCya
Gene Full Name
fibrillin 2
Modification
Conditional knockout
NCBI ID
14119 (Mouse)
Phenotype
MGI:95490
Chromosome
Chr 18 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000025497
NCBI Transcript ID
NM_010181
Target Region
Exon 2
Size of Effective Region
~0.6 kb
Overview of Gene Research
Fbn2, encoding fibrillin-2, is associated with elastin fibres [2,4]. Its products play a role in the formation of the extracellular matrix, with implications for connective tissue integrity. The extracellular matrix organization pathway is one of the associated pathways [5].

Pathogenic variants in Fbn2 cause congenital contractural arachnodactyly (CCA), an autosomal dominant connective tissue disorder. CCA is characterized by features like arachnodactyly, camptodactyly, contracture of major joints, scoliosis, pectus deformities, and crumpled ears [1,3,6]. Some Fbn2 variants may also lead to severe cardiovascular or skeletal manifestations [1,3,5].

In bladder cancer, Fbn2 expression is upregulated and can be an independent prognostic factor, influencing the tumour microenvironment [2]. In hypoxic conditions, Fbn2 expression is reduced, inhibiting elastic fiber synthesis [4]. Also, Fbn2 promotes osteoblast proliferation, mineralization, and differentiation to accelerate fracture healing [7].

In conclusion, Fbn2 is crucial for connective tissue-related biological processes. Studies on Fbn2-related disorders such as CCA, and its role in bladder cancer, hypoxia-related elastic fiber impairment, and fracture healing, help us understand its biological functions. These insights may contribute to better management and treatment strategies for these conditions.

References:
1. Yang, Shulin, Li, Zongzhe. 2024. FBN2 pathogenic variants in congenital contractural arachnodactyly with severe cardiovascular manifestations. In Connective tissue research, 65, 214-225. doi:10.1080/03008207.2024.2340004. https://pubmed.ncbi.nlm.nih.gov/38602424/
2. Lu, Zechao, Lu, Zeguang, Lai, Yongchang, He, Zhaohui, Tang, Fucai. 2023. A comprehensive analysis of FBN2 in bladder cancer: A risk factor and the tumour microenvironment influencer. In IET systems biology, 17, 162-173. doi:10.1049/syb2.12067. https://pubmed.ncbi.nlm.nih.gov/37337404/
3. Huang, Yazhou, Fang, Xingxin, Ma, Linya, Gao, Taoran, Peng, Dan. 2025. FBN2 pathogenic mutation in congenital contractural arachnodactyly with severe skeletal manifestations. In Molecular genetics and metabolism reports, 42, 101193. doi:10.1016/j.ymgmr.2025.101193. https://pubmed.ncbi.nlm.nih.gov/39911746/
4. Boizot, Jérémy, Minville-Walz, Mélaine, Reinhardt, Dieter Peter, Sigaudo-Roussel, Dominique, Debret, Romain. 2022. FBN2 Silencing Recapitulates Hypoxic Conditions and Induces Elastic Fiber Impairment in Human Dermal Fibroblasts. In International journal of molecular sciences, 23, . doi:10.3390/ijms23031824. https://pubmed.ncbi.nlm.nih.gov/35163744/
5. Chen, Jing, Xiang, Qinqin, Xiao, Xiao, Yang, Mei, Liu, Shanling. 2022. Carrying both COL1A2 and FBN2 gene heterozygous mutations results in a severe skeletal clinical phenotype: an affected family. In BMC medical genomics, 15, 154. doi:10.1186/s12920-022-01296-8. https://pubmed.ncbi.nlm.nih.gov/35804365/
6. Sun, Liying, Huang, Yingzhao, Zhao, Sen, Tian, Wen, Wu, Nan. 2022. Identification of Novel FBN2 Variants in a Cohort of Congenital Contractural Arachnodactyly. In Frontiers in genetics, 13, 804202. doi:10.3389/fgene.2022.804202. https://pubmed.ncbi.nlm.nih.gov/35360850/
7. Huang, Jian, Huang, Jun, Li, Nan, Wang, Lanfang, Xiao, Quanhao. 2025. FBN2 promotes the proliferation, mineralization, and differentiation of osteoblasts to accelerate fracture healing. In Scientific reports, 15, 4843. doi:10.1038/s41598-025-89215-6. https://pubmed.ncbi.nlm.nih.gov/39924543/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research